Multifocal Motor Neuropathy - Pipeline Insight, 2024

This “Multifocal Motor Neuropathy- Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Multifocal Motor Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Multifocal Motor Neuropathy: Understanding

Multifocal Motor Neuropathy: Overview

Multifocal motor neuropathy is a rare disorder characterized by slowly progressive muscle weakness, primarily of the arms and legs. The disorder is considered to be immune-mediated, which means there is inflammation resulting from abnormal functioning of the immune system and the presence of specific autoantibodies that target a specific protein in the body. Other symptoms including muscles cramps and wasting (atrophy) of muscles can also occur. The term multifocal means arising from two or more spots. The term motor refers to the motor nerves, which are those that carry nerve impulses from the brain to the muscles. The exact, underlying cause of this disorder is not fully understood. The disorder is acquired at some point during a person’s life; a person is not born with the disorder. Multifocal motor neuropathy usually responds to treatment with intravenous immunoglobulin. Multifocal motor neuropathy is a progressive disorder, this means that the signs and symptoms tend to worsen slowly over time. The main symptom is progressive muscle weakness of the arms and legs. Unlike other neurological disorders affecting the arms and legs, there usually is not any sensory deficits. This means that feelings of tingling or numbness or pain are not associated with the disorder. Muscle weakness often begins in the hands, causing hand weakness and affected individuals may drop objects frequently or have difficulty performing tasks that require fine motor skills such as turning a key in a lock. Fine motor skills are those that require small movements involving the hands and wrists. The exact, underlying cause of multifocal motor neuropathy is not fully understood. The disorder is believed to be caused by or related to an abnormal response of the immune system. A diagnosis of multifocal motor neuropathy is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. Asymmetrical muscle weakness without sensory problems (e.g. numbness, tingling, etc.) are the main signs of multifocal motor neuropathy. Diagnostic criteria for this disorder have been proposed by several groups. In 2012, the U.S. Food and Drug Administration (FDA) approved Gammagard Liquid 10% for the treatment of multifocal motor neuropathy. Various other medications have been tried to treat multifocal motor neuropathy including cyclophosphamide, which has shown some effectiveness in some reports, but also some toxicity.

“Multifocal Motor Neuropathy- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multifocal Motor Neuropathy pipeline landscape is provided which includes the disease overview and Multifocal Motor Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Multifocal Motor Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multifocal Motor Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Multifocal Motor Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Multifocal Motor Neuropathy.

Multifocal Motor Neuropathy Emerging Drugs Chapters

This segment of the Multifocal Motor Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Multifocal Motor Neuropathy Emerging Drugs

ARGX-117: ArgenxARGX-117 is designed to be a humanized sweeping antibody that binds specifically to C2 in a pH- and Ca2+- dependent manner. C2 is a protein in the complement cascade which, when activated, leads to cell destruction. Binding of ARGX-117 is intended to inhibit the function of C2 and downstream complement activation. By blocking complement activity, ARGX-117 has the potential to reduce tissue inflammation and the adaptive immune response. Through this proposed mechanism, ARGX-117 could represent a broad pipeline opportunity across severe autoimmune indications. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Multifocal Motor Neuropathy.

Multifocal Motor Neuropathy: Therapeutic Assessment

This segment of the report provides insights about the different Multifocal Motor Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Multifocal Motor Neuropathy

There are approx. 3+ key companies which are developing the therapies for Multifocal Motor Neuropathy. The companies which have their Multifocal Motor Neuropathy drug candidates in the most advanced stage, i.e. phase II include, Argenx.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Multifocal Motor Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Multifocal Motor Neuropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multifocal Motor Neuropathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multifocal Motor Neuropathy drugs.

Multifocal Motor Neuropathy Report Insights

• Multifocal Motor Neuropathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Multifocal Motor Neuropathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Multifocal Motor Neuropathy drugs?
• How many Multifocal Motor Neuropathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multifocal Motor Neuropathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Multifocal Motor Neuropathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Multifocal Motor Neuropathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Argenx
• Annexon biosciences
• Polyneuron Pharmaceuticals
• Biotest AG

Key Products

• ARGX-117
• ANX005
• IgG